



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-Factor VIII [KM41] Standard Size Ab04009-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human scFv format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: KM41

Alternative Name(s) of Target: AHF; FVIII; Factor 8; anti-hemophilic factor; Coagulation factor VIII; procoagulant component

UniProt Accession Number of Target Protein: P00451

Published Application(s): functional assay, inhibit, ELISA

Published Species Reactivity: Human

Immunogen: The original antibody was isolated from a human phage display library generated from the peripheral blood of an inhibitor patient and panning the library against factor VIII light chain.

Specificity: This antibody binds and epitope between amino acid R1803-K1818 of the A3-C1 domains of the human factor VIII, which also contain binding site for factor IXa. Factor VIII is a glycoprotein involved in blood coagulation. Factor VIII acts as a cofactor for factor IXa which converts factor X to the activated form Xa in the presence of calcium and phospholipids. Defects in the F8 gene, which encodes Factor VIII, result in the coagulation disorder hemophilia A.

Application Notes: The scFv version of this antibody was capable of inhibiting factor VIII activity with inhibition titre of 63 BU/mg. The scFv antibody binds human factor VIII light chain with a binding affinity of $K_d = 1.6$ nM (PMID: 11159524). It was reported that scFv KM33 inhibits the procoagulant activity of factor VIII. In view of the similar epitope specificity of scFv KM41 and CLB-CAg A (antibody which binds a synthetic peptide comprising residues R1803-K1818), it is likely that scFv KM41 competes with factor IXa for binding to the factor VIII light chain (PMID: 11159524).

Antibody First Published in: van den Brink et al. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII. Blood. 2001 Feb 15;97(4):966-72.

[PMID:11159524](#)

Note on publication: Describes the generation and epitope mapping of antibodies against A3 domain of factor VIII.

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.